Holly K. Tabor, PhD and Aaron Goldenberg, PhD, MPH
Rare genetic disease research has something to teach precision medicine about addressing some patients’ limited access to treatment. Health disparities exacerbated by high costs and limited availability of drugs can, perhaps, be mitigated when patient activism accelerates drug development.
AMA J Ethics. 2018;20(9):E834-840. doi:
10.1001/amajethics.2018.834.
Patient safety is a medical ethics issue that must be addressed through health care teams’ open communication as well as through time-outs and checklists.
AMA J Ethics. 2016;18(9):925-932. doi:
10.1001/journalofethics.2016.18.9.stas1-1609.
The Holocaust and the racial hygiene doctrine that helped rationalize it still overshadow contemporary debates about using gene editing for disease prevention.
AMA J Ethics. 2021;23(1):E49-54. doi:
10.1001/amajethics.2021.49.
Long-acting injectables powerfully augment HIV care, but broad acceptance and uptake could be compromised by what we know about experiences with antipsychotics.
AMA J Ethics. 2021;23(5):E405-409. doi:
10.1001/amajethics.2021.405.
Jessica Pierce, PhD, Marc Bekoff, PhD, Hope Ferdowsian, MD, MPH, Barbara J. King, PhD, and L. Syd M. Johnson, PhD
Our letter objects to the inclusion, in the April issue, of "Answers to Patient, Student, and Clinician Questions About How Animals Are Slaughtered and Used for Food," by Temple Grandin.
AMA J Ethics. 2023;25(6):E461-463. doi:
10.1001/amajethics.2023.461.
Introduction of an intervention that reduces the perceived risk of a given behavior may cause a person to increase risky behavior—this is called “risk compensation.”